Literature DB >> 19850156

Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: a systematic review and meta-analysis.

Marjolein Sikkema1, Pieter J F de Jonge, Ewout W Steyerberg, Ernst J Kuipers.   

Abstract

BACKGROUND & AIMS: As the risk of esophageal adenocarcinoma (EAC) and mortality in patients with Barrett's esophagus (BE) are important determinants of the potential yield and cost-effectiveness of BE surveillance, clarification of these factors is essential. We therefore performed a systematic review and meta-analysis to determine the incidence of EAC and mortality due to EAC in BE under surveillance.
METHODS: Databases were searched for relevant cohort studies in English language that reported EAC risk and mortality due to EAC in BE. Studies had to include patients with histologically proven BE, documented follow-up, and histologically proven EAC on surveillance. A random effects model was used with assessment of heterogeneity by the I(2)-statistic and of publication bias by Begg's and Egger's tests.
RESULTS: Fifty-one studies were included in the main analysis. The overall mean age of BE patients was 61 years; the mean overall proportion of males was 64%. The pooled estimate for EAC incidence was 6.3/1000 person-years of follow-up (95% confidence interval, 4.7-8.4) with considerable heterogeneity (P < .001; I(2) = 79%). Nineteen studies reported data on mortality due to EAC. The pooled incidence of fatal EAC was 3.0/1000 person-years of follow-up (95% confidence interval, 2.2-3.9) with no evidence for heterogeneity (P = .4; I(2) = 7%). No evidence of publication bias was found.
CONCLUSIONS: Patients with BE are at low risk of malignant progression and predominantly die due to causes other than EAC. This undermines the cost-effectiveness of BE surveillance and supports the search for valid risk stratification tools to identify the minority of patients that are likely to benefit from surveillance. Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 19850156     DOI: 10.1016/j.cgh.2009.10.010

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  121 in total

1.  Medical and endoscopic management of high-grade dysplasia in Barrett's esophagus.

Authors:  K K Wang; J M Tian; E Gorospe; J Penfield; G Prasad; T Goddard; M Wongkeesong; N S Buttar; L Lutzke; S Krishnadath
Journal:  Dis Esophagus       Date:  2012-03-12       Impact factor: 3.429

2.  Barrett esophagus and life expectancy: implications for screening?

Authors:  Ernst J Kuipers
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-10

3.  Biodegradable esophageal stent placement does not prevent high-grade stricture formation after circumferential mucosal resection in a porcine model.

Authors:  Eric M Pauli; Steve J Schomisch; Joseph P Furlan; Andrea S Marks; Amitabh Chak; Richard H Lash; Jeffrey L Ponsky; Jeffrey M Marks
Journal:  Surg Endosc       Date:  2012-06-09       Impact factor: 4.584

4.  Treatment for non-dysplastic Barrett's oesophagus: a well-informed, demanding patient.

Authors:  Luigi Dall'Olmo; Lorenzo Moja
Journal:  Intern Emerg Med       Date:  2010-09-03       Impact factor: 3.397

5.  Radiofrequency ablation of Barrett's esophagus: let's not get ahead of ourselves.

Authors:  Gary W Falk
Journal:  Dig Dis Sci       Date:  2010-07       Impact factor: 3.199

6.  Reduced Risk of Barrett's Esophagus in Statin Users: Case-Control Study and Meta-Analysis.

Authors:  Ian L P Beales; Leanne Dearman; Inna Vardi; Yoon Loke
Journal:  Dig Dis Sci       Date:  2015-09-19       Impact factor: 3.199

7.  Toll-like receptor 9 expression in the natural history of Barrett mucosa.

Authors:  Heikki Huhta; Olli Helminen; Joonas H Kauppila; Heikki Takala; Kalervo Metsikkö; Petri Lehenkari; Juha Saarnio; Tuomo Karttunen
Journal:  Virchows Arch       Date:  2015-04-03       Impact factor: 4.064

8.  The risk of oesophageal adenocarcinoma in a prospectively recruited Barrett's oesophagus cohort.

Authors:  B T Theron; H Padmanabhan; H Aladin; P Smith; E Campbell; P Nightingale; B T Cooper; N J Trudgill
Journal:  United European Gastroenterol J       Date:  2016-02-19       Impact factor: 4.623

9.  [Esophageal precancerous lesions: early diagnosis, treatment, and preservation of quality of life].

Authors:  A Behrens; A May; H Manner; J Pohl; C Ell
Journal:  Internist (Berl)       Date:  2013-06       Impact factor: 0.743

10.  Vitamin D Receptor Polymorphisms Are Associated with Reduced Esophageal Vitamin D Receptor Expression and Reduced Esophageal Adenocarcinoma Risk.

Authors:  Vincent T Janmaat; Anouk Van De Winkel; Maikel P Peppelenbosch; Manon C W Spaander; André G Uitterlinden; Farzin Pourfarzad; Hugo W Tilanus; Agnieszka M Rygiel; Leon M G Moons; Pascal P Arp; Kausilia K Krishnadath; Ernst J Kuipers; Luc J W Van Der Laan
Journal:  Mol Med       Date:  2015-04-21       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.